Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Most Cited Paper
in Liver Disease Diagnosis and Treatment
18 Months Post-Publication
Class of 2026
“Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
retatrutide · triple hormone receptor agonist · glucose-dependent insulinotropic polypeptide receptor · GLP-1 receptor · glucagon receptor · Metabolic dysfunction-associated steatotic liver disease · Hepatic steatosis reduction · phase 2a trial · Subcutaneous administration · dose-response relationship · body weight reduction · abdominal fat · insulin sensitivity · Lipid metabolism · Hepatic steatosis reduction · MRI-PDFF
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Liver Disease Diagnosis and Treatment Papers, Class of 2026. https://pri.pepkio.com/top-papers/liver-disease-diagnosis-and-treatment/2026. Accessed 2026-07-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459